Thursday 30 September 2010
Hosted by Clyde & Co LLP
Co-organiser: Asia-Pacific Technology Network
Co-organiser: London Biotechnology Network
Chair
- Professor Barry Furr, Former Chief Scientist, AstraZeneca
Speakers
- Louis Turner, Chief Executive, Asia-Pacific Technology Network
- "Which companies are doing what and where? An overview"
- Pranit Kumar, Director - Life Science R&D Outsourcing, EALA, Accenture
- "The challenges from Asia"
- Dr Mike Minchin, Director R&D Strategy, Astellas Pharma Europe Ltd
The rise of Asian competition is one more pressure on the established "western" parmaceutical giants. New generic champions in countries like India have been one development. In the longer run, there is an awareness of a rise in the scientific prowess of the region. Big Pharma has been responding by marketing strongly across the region and by sourcing from it. The companies are also putting manufacturing plants and research labs in the region. This seminar will ask whether Big Pharma will be able to maintain their hold on the global industry, or whether they will increasingly face major challenges coming out of Asia.
Location: Clyde & Co LLP 51 Eastcheap, London, EC3M 1JP
Map and Directions: Please Click Here
Nearest tube station: Monument
Timing: Registration from 17:00: seminar from 17:30 - 19.15 (followed by refreshments)
Pricing:
- Free to Clyde & Co clients and APTN's annual supporters
- £40 + VAT (Executives)
- £20 + VAT (Asian citizens/institutions, officials, executives from Small Companies)
- £10 + VAT (Academics),
- Free for the Media
To Register your interest - please send your details (name, institutional affiliation, email address, phone number - and the category you come under) to biz22@aptn.org
Pranit Kumar
Pranit brings a good blend of technology, business and in-depth understanding of Healthcare and Life (H&L) Science industry with experience in developing strategy, solution and services across US, UK and India for Global Top-10 H&L customers. Prior to joining Accenture, he provided thought leadership to the Life Science Practice of Satyam as Head of Strategy, Regions and Alliances by developing academia and industry partnerships and incubating life science service offerings within the non-US regions. Possessing entrepreneurial experience in developing new business and managing existing business, he was directly responsible for acquisition, incubation and growth of Top-2 Globally ranked H&L customers creating the foundation for both the Healthcare and Life Science vertical business of Satyam. In addition to business growth, he has hands-on experience in implementing change management across 10 site and 1000 customer employees across US and UK, developed sourcing strategies in conjunction with customers and implemented shared service engagement model with the delivery team to enable customers realize economies of scale, process standardization and significant cost benefits. Through-out his market facing career he has engaged with C-Level stakeholders to align, recommend and implement their strategies with predictable and tangible outcomes. In all, Pranit has 13 plus years of diverse experience in strategy, industry partnership, change management, strategic client relationship, new business development and project delivery while working with pharmaceutical, healthcare, insurance and transportation customers across US, UK and India. He has received a Master in Computer Application from Birla Institute of Technology, India and an MBA from Imperial College Business School, London
Dr Mike Minchin
After a biochemistry degree at Oxford and a Ph.D. in neurochemical pharmacology at Cambridge, Mike did 10 years postdoctoral research in Norway, Australia and the UK before entering the pharmaceutical industry. After 10 years at Wyeth Research (UK), latterly as Director of Molecular Pharmacology, the laboratory closed and he moved to the Yamanouchi Research Institute in Oxford. Mike was then appointed Director of R&D Strategy at Yamanouchi UK Ltd., and later, following the merger with Fujisawa, at Astellas Pharma Europe Ltd., reporting to the Head of Discovery Research in Japan. His research interests lie in psychiatric and neurodegenerative disorders, though in his present position he covers discovery research across all the therapeutic areas in which Astellas has an interest.
Louis Turner
Louis Turner is the Chief Executive of the Asia-Pacific Technology Network, and has been monitoring the developments in the Asian corporate and technological sectors since his first visit to Japan in 1970. He followed this up by editing the The Rise of the Newly-Industrialising Economies in the late 1970s. (Starting with Invisible Empires in 1970, which was the first popular British book on the politics of multinational companies, he has written eleven books/monographs on topics such as a history of the international oil industry, the rise of the Newly industrializing Countries, Middle Eastern Industrialization, Industrial Collaboration with Japan and the coming of Global Competition. He is currently writing a history of Japan's post-1990 investment in the UK (financed by the Great Britain Sasakawa Foundation)
During a long career at Chatham House (formerly the Royal Institute of International Affairs), he developed the concept of annual conferences with Japan (the UK-Japan High Technology Industry Forums - 1986-2005), which, with Department of Trade help, developed into five annual Forums with Korea (2000-5) and three with China (2003-5). He developed the Asia-Pacific Technology Network in 1993, building on his UK-Japanese work. Currently the Network involves some 2,500 people interested in some part of Asian technology or corporate strategy.
Currently, he is Associate Fellow, Chatham House and a Visiting Fellow, Centre for International Business University of Leeds.